Celgene Corporation (CELG)
(Delayed Data from NSDQ)
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Company News For Jan 18, 2018
by Zacks Equity Research
Companies In The News are: TIF,CSX,JUNO,CELG,FAST
J&J (JNJ) Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Promising data from several pivotal studies and a rapid pipeline progress contribute to a rally in Johnson & Johnson's (JNJ) shares.
Novartis sBLA for CAR-T Therapy Kymriah Accepted by FDA
by Zacks Equity Research
Novartis (NVS) gets a significant boost with the FDA approval of CAR-T Therapy Kymriah and the company is now looking to expand the therapy's label.
3 Top-Ranked Drug Stocks that are Broker Favorites
by Arpita Dutt
With the pharma and biotech sector performing well in 2017, here is a look at three drug stocks including Vertex (VRTX) that are broker favorites.
Is Celgene (CELG) Looking to Take Over Juno Therapeutics?
by Zacks Equity Research
There are reports that Celgene (CELG) is in talks to acquire Juno Therapeutics to strengthen its portfolio given the recent series of setbacks.
Biotech Stock Roundup: Juno Surges on Acquisition Rumor, Concert Down on Patent News
by Arpita Dutt
Is Celgene (CELG) in talks with Juno regarding a possible acquisition deal? This was the main news in the biotech sector this week.
Concert Pharmaceuticals Plunges on Patent Petition Setback
by Zacks Equity Research
Shares of Concert Pharmaceuticals (CNCE) nosedive after the Patent Trial and Appeal Board decided not to grant a Post Grant Review petition in patent '335 dispute with Incyte.
The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
Key Takeaways from Pfizer & 3 Other Drug Stocks at Healthcare Conference
by Arpita Dutt
Here is a look at key takeaways from presentations made by four major pharma and biotech stocks including Pfizer (PFE) at the annual J.P. Morgan healthcare conference.
Celgene Provides 2017 Preliminary Results & 2018 View
by Zacks Equity Research
Celgene Corporation (CELG) provided preliminary results for 2017 and upbeat guidance for 2018. The company suffered a few setbacks of late and is looking to bolster its pipeline.
Celgene to Acquire Impact Biomedicines to Boost Pipeline
by Zacks Equity Research
Celgene (CELG) announced that it will acquire Impact Biomedicines to bolster its oncology pipeline given the recent series of setbacks.
Will J&J (JNJ) Continue to Tread Growth Path This Year?
by Zacks Equity Research
Johnson & Johnson's (JNJ) stock was up last year. The positive trend is likely to continue this year as well.
What Drives Juno Therapeutics (JUNO) Above 150% This Year
by Zacks Equity Research
We take a look at the factors especially the focus on CAR-T therapy that led to the phenomenal growth in Juno Therapeutics (JUNO) share price in 2017.
Celgene (CELG) in Troubled Waters in '17: What Does 2018 Hold?
by Zacks Equity Research
Celgene's (CELG) stock has been under pressure due to pipeline setbacks. We expect an acquisition in the offing to bolster its portfolio.
Company News For Dec 28, 2017
by Zacks Equity Research
Companies In The News are: TSLA,BA,CELG,WATT
4 Biotech Stocks Ready to Crush the Market in 2018
by Zacks Equity Research
The biotech sector has performed well in 2017 and we expect the momentum to continue in 2018 driven by new drug approvals. Here, we list stocks which might be worth adding to your biotech portfolio for 2018.
Agios (AGIO) Files NDA for Leukemia Candidate in the U.S.
by Zacks Equity Research
Agios (AGIO) submits new drug application to the FDA for ivosidenib for relapsed or refractory acute myeloid leukemia and IDH1 mutation. The company has also filed request for a priority review.
Why is Corcept's Stock Up More Than 150% So Far This Year?
by Zacks Equity Research
We take a look at the factors that drove the phenomenal growth in share price of Corcept (CORT) in 2017.
Biotech Stock Roundup: BIIB, CELG Hit by Pipeline News, Acquisition Deals for Ignyta, Sucampo
by Arpita Dutt
A couple of acquisition agreements as well as pipeline news from Celgene (CELG) and Biogen were the key highlights this week in the biotech sector.
Celgene (CELG) Down on Discouraging Data on Revlimid
by Zacks Equity Research
Celgene (CELG)'s stock declined as the phase III study, REVELANCE, for the label expansion of key drug Revlimid for untreated follicular lymphoma patients failed.
4 Biotech Stocks That More Than Doubled This Year
by Zacks Equity Research
We take a look at a few biotech stocks whose price has increased more than 100% in 2017.
Biotech Stock Roundup: ASH Data in Focus, Gilead to Buy Cell Design Labs
by Arpita Dutt
The annual meeting of the American Society of Hematology was the key highlight this week with several companies like bluebird (BLUE) presenting data on their investigational treatments.
Juno Reports Additional Data on CAR-T Therapy, Shares Drop
by Zacks Equity Research
Juno (JUNO) releases additional results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate, JCAR017.
Bluebird's Shares Jump on Strong Data for CAR-T Therapy
by Zacks Equity Research
bluebird (BIRD) announced updated results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate- bb2121.
Gilead (GILD) Posts Updated Data on CAR-T Therapy Yescarta
by Zacks Equity Research
Gilead (GILD) announced follow-up data from a phase II study, on its CAR-T therapy, Yescarta for treatment of refractory large B-cell lymphoma.